Kalender M Emin, Sevinc Alper, Kucukdurmaz Zekeriya, Balik Ahmet, Sari Ibrahim, Camci Celalettin
Department of Medical Oncology, Gaziantep Oncology Hospital, Gaziantep, Turkey.
Onkologie. 2007 Nov;30(11):568-70. doi: 10.1159/000108640. Epub 2007 Oct 5.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract. Gastric cancer is the second most common neoplasm worldwide. Prostate cancer is the most common non-cutaneous cancer. The most frequently encountered second malignancies in patients with prostate adenocarcinoma include carcinomas of the bladder, stomach, and colon, followed by cutaneous and hematolymphoid malignancies.
We report the case of a 60-year-old male patient who was diagnosed with GIST and started on imatinib mesylate 400 mg/day. 2 years later, the patient was diagnosed with gastric adenocarcinoma, and a subtotal gastrectomy and gastrojejunostomy were performed. At followup 6 months later, prostate-specific antigen (PSA) levels were elevated, and a prostate biopsy showed a prostate adenocarcinoma.
This is the second report of metachronous prostate cancer, gastric cancer, and GIST in the English language literature.
胃肠道间质瘤(GIST)是胃肠道最常见的间叶性恶性肿瘤。胃癌是全球第二常见的肿瘤。前列腺癌是最常见的非皮肤癌。前列腺腺癌患者最常遇到的第二原发恶性肿瘤包括膀胱癌、胃癌和结肠癌,其次是皮肤和血液淋巴系统恶性肿瘤。
我们报告一例60岁男性患者,该患者被诊断为GIST并开始服用甲磺酸伊马替尼400毫克/天。2年后,该患者被诊断为胃腺癌,并接受了胃大部切除术和胃空肠吻合术。6个月后的随访中,前列腺特异性抗原(PSA)水平升高,前列腺活检显示为前列腺腺癌。
这是英文文献中关于异时性前列腺癌、胃癌和GIST的第二篇报道。